The development of angiotensin-converting enzyme inhibitors and selective angiotensin type 1 (AT 1 )-receptor antagonists has provided new insights into understanding the mechanism of the renin-angiotensin system (RAS) in the pathophysiology of cardiovascular disease. There is good evidence from meta-analyses that shows that inhibition of the RAS achieves organ protection features that go beyond blood pressure control. Candesartan cilexetil, a new angiotensin II receptor
Introduction
Hypertension is a major risk factor for myocardial infarction, stroke, and renal and peripheral vascular disease. Epidemiological studies have found a direct linear correlation between the risk of cardiovascular disease and blood pressure levels. Long-term elevations in blood pressure are associated with hypertrophy, hyperplasia and remodelling of the heart, as well as vascular and renal damage. While some of these changes are compensatory adaptations to the increased workload associated with raised blood pressure, structural remodelling of the kidney, heart and vasculature may also occur independently of blood pressure levels. 1 It would appear that the renin-angiotensin system (RAS) plays a central role in the acute and chronic development of cardiovascular disease. Yet, it is only recently, with the development of angiotensin-converting enzyme (ACE) inhibitors and selective angiotensin type 1 (AT 1 ) receptor antagonists, that the full significance of RAS in the acute and chronic development of cardiovascular disease has been realised. There is good evidence from meta-analyses that shows that inhibition of the RAS achieves organ protection features that go beyond blood pressure control. [2] [3] [4] This paper reviews the possible mechanisms of ACE inhibition and angiotensin II receptor antagonism in organ protection and hypothesises on the possible clinical benefits that may be achievable with prolonged angiotensin II receptor blockade.
antagonist, is characterised by its tight binding to and slow dissociation from the AT 1 receptor, and high antagonistic potency, resulting in long-lasting antagonistic effects. It is anticipated that these pharmacological characteristics may bring additional benefits to patients, not only for the management of essential hypertension but also for the management of end-organ damage.
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Blocking the RAS in essential hypertension
Angiotensin II, the key effector peptide of the RAS, exerts a variety of actions in the regulation of arterial blood pressure and the maintenance of fluid and electrolyte homeostasis. Blood pressure is raised by a direct pressor action, increased sympathetic transmission, water retention (via direct action on sodium reabsorption, or indirectly via increased aldosterone release) and altered renal haemodynamics. Angiotensin II also acts centrally to induce thirst and drinking behaviour, to attenuate the baroreceptor reflex and to release arginine vasopressin and other hormones such as adrenocorticotrophic hormone and oxytocin. 5, 6 Blockade of the RAS using ACE inhibitors or angiotensin II receptor antagonists (AIIRAs) results in an acute hypotensive response in sodium-depleted animals or humans. In conditions associated with elevated plasma angiotensin II levels, such as experimental or clinical renovascular hypertension and congestive heart failure, these agents bring about a marked depressor response. 7 In most acute studies, the magnitude of the depressor response can be predicted by the pre-treatment plasma levels of renin and consequently of angiotensin II, indicating a causal relationship. 7 Although the acute blood pressure-lowering effects of RAS inhibition correlate with initial plasma renin activity, the chronic response bears little relation to pre-treatment levels. 7 Both ACE inhibitors and AIIRAs can lower blood pressure levels in hypertensive patients whose plasma renin levels are normal or even low, but the magnitude of the antihypertensive response is often less pro-nounced in patients with low renin levels. While circulating angiotensin levels have an important endocrine function in acute volume and blood pressure homeostasis, the tissue RAS within the brain, heart, kidney, adrenals and blood vessels acts as a regulator or amplifier of local function. 8 Angiotensin II, which is released by vascular cells, has both an autocrine function (causing endothelial dysfunction and smooth muscle hypertrophy) and a paracrine function (influencing smooth muscle tone). 8 It has been postulated that abnormal tissue RAS activities are contributors to the development and maintenance of essential hypertension. 8, 9 Both ACE inhibitors and AIIRAs prevent and/or reverse most of the vasculature changes in experimental and clinical hypertension.
ACE inhibition and end-organ damage
Intervention with ACE inhibitors, introduced 20 years ago as antihypertensive agents, has become one of the most successful therapeutic approaches for reducing left ventricular mass, 2 decreasing overall mortality and death from chronic heart failure, 10 improving the outcome for patients with ventricular systolic dysfunction and symptomatic heart failure, 11 reducing post-myocardial infarction mortality, 12 retarding the progression of renal insufficiency in insulin-dependent diabetes mellitus (IDDM), improving renal function in IDDM and retarding the progression of non-diabetic chronic renal disease.
13-15 ACE inhibitors have recently been shown to reduce the rate of death, myocardial infarction and stroke in a broad range of patients with a high cardiovascular risk at baseline. 16 In elderly hypertensive patients, ACE inhibitors have been shown to reduce the incidence of fatal and non-fatal cardiovascular events 17 to the same extent as conventional therapy with diuretics or ␤-blockers. Research into mechanisms of ACE inhibition in endorgan damage has focused on the dual role of the circulating RAS as well as the tissue RAS on endorgan damage. 8, 18 Angiotensin II is recognised as a growth-promoting factor that contributes in an autocrine/paracrine fashion to structural alterations in various organs, most notably the heart, vasculature and kidneys. 6, 19 It is also involved in cardiac left ventricular hypertrophy and fibrosis, vascular media hypertrophy or neointima formation, structural postinfarct remodelling and nephrosclerosis, neointima formation, post-infarction remodelling and nephrosclerosis, apart from affecting blood pressure. 5, 20, 21 The conversion of angiotensin I to the active octapeptide angiotensin II is catalysed by both circulating ACE as well as a membrane-bound form that is found abundantly in the vascular endothelium as well as the renal proximal tubules, the myocardium and adrenal glands. [22] [23] [24] Prolonged inhibition of tissue ACE in the heart vasculature and kidney may be especially important in pathological states. While it is thought that under normal physiological conditions the concentrations of ACE remain constant, under pathological conditions such as left ventricular hypertrophy, myocardial infarction, heart failure and atherosclerosis, the expression and activity of ACE may be dramatically increased. 18, [25] [26] [27] Normally absent from vascular smooth muscle, recent immunohistochemical evidence indicates that ACE can be detected in migrated macrophages and smooth muscle cells of atherosclerotic coronary arteries during the progression of atherosclerosis, and in the early healing processes following percutaneous transluminal coronary angioplasty (PTCA). 28 Angiotensin I is not the only substrate for ACE, which also degrades bradykinin and a number of other peptides (Figure 1) . 29 Bradykinin, produced locally within tissues, is thought to have beneficial effects promoting vasodilatation, natri/diuresis and antiremodelling. In animal experiments, the abilities of ACE inhibitors to potentiate kinins as well as inhibit the formation of angiotensin II have both been demonstrated to contribute to organ protection in various models of cardiovascular disease. [30] [31] [32] However, it is still not clear to what degree the potentiation of kinins adds to the beneficial effects of ACE inhibitors in clinical practice. It seems that an increase in bradykinin contributes to the shortterm effects of ACE inhibition on blood pressure. 33 However, the effect of ACE inhibitors on bradykinin does not appear to contribute substantially to the long-term effects of the drug, at least not in patients with congestive heart failure. 34 The local production of angiotensin II augmenting a tissue-specific response independent of the circulatory RAS presents a powerful new model for the pathogenesis of cardiovascular disease. This theory is supported by the recent identification of local tissue enzymes such as chymase in the heart and vasculature which indicate a role of ACE-independent pathways in the production of angiotensin at a local tissue level. 35 In addition, other proteases such as cathepsin G [36] [37] [38] and elastases 39 are thought to enhance angiotensin II generation locally at sites of inflammation and tissue injury.
Although it is still controversial whether active renin is derived directly from the kidney or synthesised locally in the heart or blood vessels, 40, 41 all other major components of the RAS have been localised in the heart and blood vessels. Thus, both circulating and tissue angiotensins play important roles in cardiovascular homeostasis. Studies are now underway to determine the relative importance of the circulatory versus tissue-specific regulatory mechanisms on the production of angiotensin II under different pathological conditions.
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Characterisation of the angiotensin II receptors
The effects of angiotensin II receptor ligands are mediated predominantly through two pharmacologically and physiologically distinct mammalian angiotensin receptors designated AT 1 and AT 2 .
1,42-44
The AT 1 receptor mediates the classical actions of angiotensin II, which include: blood pressure regulation, the drinking response and angiotensin IIinduced cell hypertrophy and hyperplasia 29 ( Table  1 ). In rodents, the AT 1 receptor seems to exist in two isoforms (AT 1a and AT 1b ). While sequence information seems to indicate that these isoforms also exist in humans, only one human gene for the AT 1 receptor has been characterised on chromosome 3. AT 1a receptors are found mainly in vascular smooth muscle suggesting that this subtype plays a role in vasoconstriction. The prevalence of the AT 1b receptor subtype within the anterior pituitary, adrenal glands, uterus and several periventricular brain areas would seem to indicate that this receptor is involved in hormonal secretion and central osmotic control. 45 The binding of angiotensin II to specific extracellular sites on the AT 1 receptor results in the activation of phospholipases C, D and A 2 via the G protein (G q ) or inhibition of adenylate cyclase via the G protein (G i ). 42, 46, 47 Phospholipase C activation results in the generation of 1,4,5-triphosphate and diacylglycerol, the subsequent activation of protein kinase C and an increase in intracellular calcium. 42 The rise in intracellular calcium is associated with
Journal of Human Hypertension typical responses such as vasoconstriction, renal salt and water retention and changes in glomerular filtration rates and renal blood flow. The cascade induced by phospholipase D leads to the formation of fatty acids such as arachidonic acid, which is a precursor of leukotrienes and prostaglandins. 40 In addition, angiotensin II-induced cell hypertrophy and hyperplasia are both mediated through the AT 1 receptor. Protein kinase C as well as elevated intracellular calcium levels have been shown to promote growth-related inducible transcriptional factors such as c-fos, c-myc and c-jun involved in the stimulation of mitogenesis. 48 An AT 1 -receptor-mediated effect also induces platelet-derived growth factor ␣ (PDGF-␣) and transforming growth factor ␤ 1 (TGF-␤ 1 ), which is directly coupled to the expression of growth factors and smooth muscle cell proliferation. 49 Significantly, recent research indicates that angiotensin II also mediates proliferative effects through the Jak/STAT signalling pathway, which leads to the transcription activation of early growthresponse genes. 50, 51 While much less is known about the functional properties of the AT 2 receptor, it would appear that it mediates the effects of angiotensin II on growth control and cell differentiation, as well as neuronal differentiation and apoptosis [52] [53] [54] [55] [56] (Table 2 ). The AT 2 -receptor-mediated effects down-modulate the actions by the AT 1 receptor, resulting in decreased cellular proliferation, modulation of AT 1 -mediated vasopressin release in certain experimental conditions and a decreased vasoconstrictor response. When the AT 1 receptors are blocked, angiotensin II appears to have an enhanced depressor response, which is reversed by PD-123177, a selective antagonist at the AT 2 receptor. It has been hypothesised that, under certain pathophysiological conditions, Mapping the distribution of the AT 1 and AT 2 receptors in normal and diseased heart and blood vessels has provided a morphological basis for understanding the physiological and pathophysiological role of these receptors. The AT 1 receptor is the predominate subtype in human cardiovascular tissue and is responsible for acute cardiovascular actions such as regulation of vascular tone and extracellular fluid volume. In the great vessels of rat and human heart, the AT 1 receptors are present at high levels in smooth muscle cells. By contrast, AT 2 receptors predominate in the adventitia of the human renal, arcuate and interlobular arteries and are detectable in the media of great vessels and atrial and ventricular homogenates of the rat heart, 25 but are also present in the vascular endothelium. 52, 56 In the human heart, the expression pattern of the AT 2 receptor may be different from the pattern of expression in the rat heart. 57 Tsutsumi et al 58 found that the proportion of AT 2 receptors in human left ventricular tissue was approximately 41% of the total angiotensin II binding sites. While the number of binding sites for angiotensin II is confirmed by others, the number of AT 2 receptors differ between studies. Tsutsumi et al 58 found that expression of the AT 2 receptor was sensitive to the experimental conditions. However, it is the relative abundance of the AT 2 receptor in foetal tissue during late gestation that first alerted scientists to its role in growth inhibition and differentiation of vascular smooth muscle cells. 59, 60 Experiments in utero in the presence of the AT 2 -receptor antagonist (PD-123319) and in 'AT 2 -receptor knock-out mice' have demonstrated the modulatory role of the AT 2 receptor in the structure and function of blood vessels. Disruption of the AT 2 -receptor gene can result in an increased basal blood pressure as well as an increased vasoconstriction response to angiotensin II. 55 In adults with certain pathological conditions such as vascular balloon injury or inflammation induced by cuff placement, the AT 2 receptor is re-expressed (Figure 2) .
The function of the AT 2 receptor was evaluated by Yamada et al 61 by transfecting either the control vector or the AT 2 -receptor vector to the rat aortic vascular smooth muscle cell (which expresses very low levels of endogenous AT 2 receptor). The study found that under control conditions, angiotensin II significantly increased vascular smooth cell numbers via the AT 1 receptor (this response was abolished by selective inhibition of the AT 1 response). With the coexpression of the AT 2 receptor, angiotensin II had little or no effect on cell numbers. Treatment of these cells with the AT 2 -receptor antagonist PD-1233319 unmasked the proliferative response of the AT 1 receptor. Consistent with these results, Stoll et al 52 also observed an antiproliferative influence of the AT 2 receptor on cultured coronary endothelial cells. By transfecting an AT 2 -receptor expression vector into the balloon-injured rat carotid artery, Nakajima et al 59 reported that coexpression of the AT 2 receptor attenuated neointimal formation. Selective AT 2 -receptor blockade reversed this effect. 59 Experiments evaluating the cellular effects of AT 2 receptors in the myocardium are currently inconclusive. 55 However, there are several observations that point to a role of AT 2 receptors in the pathogenesis of human cardiac diseases and the subsequent remodelling process. 55 Upregulation of AT 1 -and AT 2 -receptor expression have been reported in human cardiac disease such as cardiac hypertrophy, myocardial infarction and in mechanical stretchinduced hypertrophy of myocytes. 57, 62 However, in failing human hearts, the relative ratio of AT 2 :AT 1 receptor expression is increased due to the downregulation of the AT 1 receptor. 63 Comparisons of tissue from regions of localised damage with adjacent normal myocardium in human hearts have shown that endocardial, interstitial, perivascular and infarcted regions in the ventricles of patients with end-stage ischaemic heart disease or dilated cardiomyopathy each exhibited a significantly greater density of high-affinity AT 2 -binding sites than adjacent non-infarcted myocardium. The regions showing the greatest increase in AT 2 -binding sites correspond to areas of fibroblast proliferation and collagen deposition. 58, 64 These observations suggest that under pathological conditions, the expression of the AT 2 receptor plays some role in cardiac remodelling in humans, possibly being increased to control the excessive growth mediated via the AT 1 receptor or other growth factors. 56 Although the mechanism by which AT 2 -receptor expression is increased is unknown, Ichiki et al 65 and Kambayashi et al 66 reported the upregulation of 
Role of AT 2 receptors in the regulation of blood pressure and renal function
Recent studies have demonstrated that stimulation of AT 2 receptors induces vasodilation and natriuresis, thus opposing the vasoconstriction and antinatriuretic effects of angiotensin II through the AT 1 receptors. 67 The AT 2 receptor stimulates a bradykinin-nitric oxide-cyclic GMP vasodilation cascade in blood vessels and in the kidney. It also stimulates the conversion of prostaglandin E 2 to prostaglandin F 2␣ . AT 1 -receptor blockade could therefore be reinforced by stimulation of AT 2 receptors by increased levels of angiotensin II, due to interruption of the negative feedback loop on renin secretion.
AT 1 -receptor blockade of RAS
While both ACE inhibitors and AIIRAs are effective in the inhibition of the RAS, they differ significantly in their effects on the components of the system. ACE inhibition results in reduced levels of angiotensin II and elevated levels of renin and possibly of bradykinin, while selective AT 1 -receptor blockade increases plasma renin and consequently angiotensin II by a normal feedback regulatory mechanism and has no direct effect on bradykinin metabolism. As a consequence, selective blockade of angiotensin II at the AT 1 receptor may potentiate the beneficial Journal of Human Hypertension effects of angiotensin II at the AT 2 receptor in terms of blood pressure regulation and growth and remodelling of cardiac and vascular tissue. 56 If the AT 2 receptor contributes to the pathogenesis of cardiovascular disease and consequent cardiac remodelling in humans, AT 1 -receptor antagonists may provide some unique cardioprotective benefits. 55 In experimental animals with heart failure, AT 1 -receptor antagonists have been shown to have cardioprotective effects and to improve cardiac function. Liu and colleagues, 68 using a model of heart failure in rats induced by myocardial infarction, have demonstrated that AT 1 -receptor blockade improved cardiac function and decreased interstitial collagen deposition and cardiomyocyte size, and that these differences were blocked by the AT 2 antagonist, suggesting that the beneficial effects on the AIIRAs were, in part, due to stimulation of the AT 2 receptor. Part of this effect may be due to an AT 2 -mediated stimulation of tissue nitric oxide (NO) and cGMP levels. 69 Despite the success of ACE inhibitors in the clinical management of cardiovascular disease, mortality remains high in patients with chronic heart failure. This may be due, in part, to the ACE-independent pathways for angiotensin II formation. 70 In vitro evidence indicates that a major angiotensin II-forming enzyme in the human heart is chymase, a mast-cellderived chymotrypsin-like serine protease. 35 The highest levels of this enzyme are found in the ventricles, while ACE levels are highest in the atria. Urata et al 35 proposed that the different cellular and regional distributions of ACE and heart chymase in the heart as well as the blood vessels implies distinct pharmacological roles of these angiotensin IIforming enzymes. Cardiac chymase has a very high affinity for angiotensin I but not for bradykinin and is not blocked by ACE inhibitors. There is little evidence for the production of angiotensin II by chymase in the normal heart. 71 However, there is evidence that cardiac chymase is increased in pathophysiological states such as heart failure and following myocardial infarction. 35 Theoretically, new therapeutic approaches with selective angiotensin AT 1 -receptor antagonists could bring additional benefits over ACE inhibition in patients with a failing heart. 72, 73 However, results of the ELITE II follow-up trial, which compared captopril (50 mg three times daily) and losartan (50 mg daily) in elderly patients with heart failure, failed to demonstrate a superiority of AT 1 -receptor blockade over ACE inhibition in terms of cardiovascular benefit, even though losartan was better tolerated than captopril. 74 It is, however, too soon to draw firm conclusions on the use of AT 1 -receptor antagonists in heart failure because the losartan dosage used in the ELITE II trial was low and the blockade of RAS achieved was probably much lower than that achieved with higher doses of captopril. Other on-going trials (CHARM I,II, III, Val-HeFT, Valiant, OPTIMAAL) will probably give the definite answer.
Pharmacological properties of candesartan cilexetil
A variety of AIIRAs have been introduced for the treatment of hypertension. They are all selective for the AT 1 receptor, but differing pharmacokinetic properties may be important in considering the wider effects of AIIRAs. Candesartan cilexetil binds tightly and dissociates slowly from the AT 1 receptor and is an insurmountable antagonist in the presence of angiotensin II. 75, 76 It has recently been shown that, in fact, all AT 1 -receptor antagonists are competitive antagonists, with tight-binding and very slow dissociation from the receptor. 77 This is especially true for candesartan, 78 which has demonstrated higher direct angiotensin II antagonistic activity in vivo than irbesartan, valsartan and losartan. 79, 80 Thus, the effects of candesartan are likely to be long lasting and less easily overcome by increased endogeneous angiotensin II. In a model of mild sodium depletion in normal volunteers, candesartan cilexetil 16 mg achieved a more prolonged and more potent blockade of the RAS (as defined by the AUC 0-24h plasma active renin levels) than either losartan 50 mg 81 or valsartan (80 mg or 160 mg; P Ͻ 0.05). 82 These pharmacological characteristics may be related to the long duration of action of candesartan cilexetil in the clinic. 83 In hypertensive patients, the reduction in diastolic and systolic blood pressure with candesartan cilexetil 16 mg over 0-36 h was significantly greater (P Ͻ 0.05) than with losartan 100 mg (Figure 3) . 84 Candesartan cilexetil has been shown to protect against end-organ damage in models of stroke-prone spontaneously hypertensive rats (SHRSP), DOCA/salt hypertensive rats, Dahl hypertensive rats and five-sixths of nephrectomised rats. 85 In the SHRSP and DOCA-salt hypertensive rats, candesartan markedly reduced the incidence of stroke and renal injury even at doses that had no effect on blood pressure, suggesting the tissue protective effects of angiotensin AT 1 antagonists are not attributable simply to the normalisation of blood pressure. In the heart, kidney and vascular tissues of SHRSP and the kidney of DOCA-salt hypertensive rats, mRNA for TGF-␤ 1 and extracellular matrix components (fibronectin, collagen type I, III and IV and laminin) were increased, and the increase in gene expression was inhibited by candesartan cilexetil. 85 Furthermore, there is evidence that angiotensin AT 1 -receptor antagonists such as candesartan directly inhibit hypertrophy or proliferation of cultured cardiac myocytes and non-myocytes (fibroblasts), cultured mesangial cells and cultured vascular smooth muscle cells when stimulated by angiotensin II. 85 An in vivo study of spontaneously hypertensive rats has investigated the effect of candesartan cilexetil and compared it with that of the vasodilator hydralazine on blood pressure and cardiovascular structure. 86 While the untreated rats became hypertensive, candesartan cilexetil or hydralazine both blunted the increase in blood pressure. Candesartan reduced left ventricular weight, left ventricular wall thickness, transverse myocyte diameter, the relative amount of V3 myosin heavy chain and interstitial fibrosis. By contrast, treatment with hydralazine showed a small effect in preventing increased left ventricular wall thickness, but did not have a significant effect on any of the other parameters.
To further elucidate the effect of angiotensin II, an in vitro study was also carried out by the same authors, in which neonatal rat myocytes were cultured on deformable silicone dishes. Stretching cardiomyocytes activated second messengers such as protein kinase C, Raf-1 kinase and mitogen-activated protein (MAP) kinase -increasing protein synthesis, enhancing endothelin (ET)-1 release and activating the Na/K ion exchanger. 86 Pre-treatment with candesartan cilexetil diminished the increases in phenylalanine incorporation, MAP kinase activity and fos gene expression induced by the stretching of cardiomyocytes. 86 The inability of ACE inhibitors to reduce the levels of angiotensin II produced by chymase in the heart also affects local tissue remodelling. Candesartan cilexetil or enalapril were administered to dogs twice daily for 5 weeks. 87 After the first week of active drug therapy, the common carotid and femoral arteries were unilaterally injured by balloon catheterisation. In the common carotid arteries, both ACE and chymase activities increased, with chymase showing the greater increase; in the femoral artery, only ACE was increased by the injury. As might be predicted from this enzyme distribution, candesartan cilexetil significantly suppressed the formation of intimal hyperplasia in both the carotid and femoral arteries, while enalapril significantly suppressed intimal hyperplasia in the femoral but not the carotid arteries. 87 Candesartan cilexetil and enalapril reduced blood pressure almost equally, but enalapril increased plasma renin activity more strongly, and significantly decreased vascular and plasma ACE activities. These results demonstrate that the local production of angiotensin II is involved in the hyperplasia seen in injured intima, and that differences exist in the tissue distribution of the angiotensin II synthetic enzymes, ACE and chymase, which results in a difference in the ability of ACE inhibitors and AIIRAs to prevent hyperplasia in different regions of the vascular system.
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Conclusions
The development of selective AT 1 -receptor antagonists has provided new insights into the understanding of the mechanism of the RAS in the pathophysiology of cardiovascular disease. Candesartan cilexetil, a new AIIRA, is characterised by its tight binding to and slow dissociation from the AT 1 receptor and its high antagonistic potency, resulting in long-lasting antagonistic effects. It is anticipated that these pharmacological characteristics may bring additional benefits to patients, not only for the management of essential hypertension but also for the management of end-organ damage. The results of on-going clinical studies are awaited with interest to evaluate whether experience in humans supports the experience in animal models.
